Adaptive Biotechnologies (ADPT) Operating Leases (2020 - 2026)

Adaptive Biotechnologies has disclosed Operating Leases across 7 years of filings, most recently posting $69.1 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $69.1 million, down 9.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.1 million (down 9.58% YoY), and the FY2025 annual result was $70.2 million, down 11.27% from the prior year.
• Operating Leases came in at $69.1 million for Q1 2026 at Adaptive Biotechnologies, down from $70.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $105.0 million in Q1 2022 to a low of $69.1 million in Q1 2026.
• The 5-year median for Operating Leases is $86.9 million (2024), against an average of $86.7 million.
• Across the five-year window, Operating Leases gained 10.21% in 2022 and declined 12.04% in 2025, its largest moves.
• Adaptive Biotechnologies' Operating Leases stood at $98.8 million in 2022, then decreased by 9.5% to $89.4 million in 2023, then declined by 11.46% to $79.1 million in 2024, then declined by 11.27% to $70.2 million in 2025, then fell by 1.58% to $69.1 million in 2026.
• The last three Operating Leases figures came in at $69.1 million (Q1 2026), $70.2 million (Q4 2025), and $72.4 million (Q3 2025), per Business Quant data.